Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk(Genmab (Netherlands)), Paul W.H.I. Parren(Leiden University Medical Center)
Cited by 502
Related Papers
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
|The Journal of Immunology|2010|1k
Dual Mode of Action of a Human Anti-Epidermal Growth Factor Receptor Monoclonal Antibody for Cancer Therapy
|The Journal of Immunology|2004|149
Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
|Molecular Cancer Therapeutics|2016|131